RNA - Bionatura journal

Bionatura Journal
Ibero-American Journal of Biotechnology and Life Sciences
ISSN 3020-7886
Go to content
The keynotes and panels from the event "RNA Revolution in Oncology: From Bench to Bedside" will be published in the first issue of Bionatura Journal in 2025.
Call for Contributions!
We invite all researchers and professionals who have articles related to the theme of the event to submit their papers for consideration in this special issue.
How to submit your article:
Visit the Bionatura Journal submission page: https://bionaturajournal.com/submit-a-manuscript.html
In the subject line of the email, clearly specify that your submission is for the special issue on "RNA Revolution in Oncology".
Don't miss the opportunity to publish your research in this special issue of Bionatura Journal and contribute to the advancement of RNA-based oncology.
Submission deadline: January 15, 2025

We look forward to receiving your valuable contributions!

#RNARevolutionOncology #RNAOncology #CancerResearch

RNA Revolution in Oncology: From Bench to Bedside
Basic Science:
  • Non-coding RNAs and their role in cancer development and progression: This could include  discussions on microRNAs, long non-coding RNAs, and circular RNAs,      exploring their mechanisms of action and potential as therapeutic targets.
  • RNA modifications and their impact on cancer biology: This topic could delve into the various chemical modifications that RNA molecules undergo and how these      modifications influence gene expression and cancer hallmarks.
  • RNA editing and its potential for cancer therapy: This session could explore the exciting field of RNA editing technologies like CRISPR-Cas systems and their potential for      correcting disease-causing mutations.
  • RNA-protein interactions and their role in cancer: This topic could explore the intricate interplay between RNA molecules and proteins, which can be exploited for      developing novel cancer therapeutics.
Translational Science and Clinical Applications:
  • RNA-based cancer vaccines: This session could discuss the development and clinical trials of RNA vaccines designed to stimulate the immune system to fight cancer cells.
  • RNA interference  (RNAi) for cancer treatment: This could explore the use of siRNA and shRNA molecules to silence the expression of oncogenes, potentially leading to new cancer therapies.
  • Therapeutic applications of antisense oligonucleotides: This session could delve into the use of  synthetic oligonucleotides that bind to specific RNA targets and modulate  their function for cancer treatment.
  • Delivery systems for RNA therapeutics: A crucial aspect of RNA-based therapies, this session could discuss developing efficient and safe methods to deliver RNA molecules into cancer cells.
  • Clinical trials of RNA-based cancer therapies: This could provide an overview of the current landscape of clinical trials evaluating the safety and efficacy of various RNA-based therapies in cancer patients.
Emerging Areas:
·         Exosome RNA and Cancer: Exosomes are tiny membrane vesicles released by cells that can contain RNA molecules. Research is ongoing to explore the role of exosomal RNA in cancer progression and its potential as a therapeutic target or diagnostic tool.
·         Circular RNAs (circRNAs) and Cancer: CircRNAs are a recently discovered class of non-coding RNAs with unique structures. Their role in cancer biology is still being unraveled, but early studies suggest they may be involved in tumorigenesis and metastasis.
·         RNA-protein Interactions and Cancer Drug Discovery: Understanding the intricate interactions between RNA molecules and proteins can provide valuable insights for developing novel cancer drugs. Researchers are exploring targeting these interactions to disrupt crucial cellular processes in cancer cells.
RNA therapeutics Production
1. Design and Development:
  • Target identification and selection: Scientists first identify a specific disease-causing gene or pathway and design the RNA molecule to target it. This could involve mRNA replacing a dysfunctional protein, siRNA silence a  specific gene, or other RNA-based approaches.
  • Sequence  optimization: The RNA sequence is carefully optimized to ensure efficient production, stability within the body, and specific targeting of the desired molecule. Researchers may modify the RNA  structure or add specific sequences to enhance its functionality.
  • Delivery system design is crucial, as RNA molecules are naturally fragile and      prone to degradation. Scientists develop delivery systems, often lipid  nanoparticles (LNPs), to encapsulate and protect the RNA during transport into target cells.
2. Plasmid DNA Production:
  • Plasmid  construction: A circular DNA molecule containing the desired RNA sequence is created. This plasmid is a template for large-scale RNA production in the next step.
  • Large-scale plasmid DNA amplification: Using specialized techniques, millions of copies of the plasmid DNA are produced to ensure sufficient material for RNA synthesis.
3. In Vitro Transcription (IVT):
  • Enzymatic RNA synthesis: The purified plasmid DNA is used as a template  in an in vitro transcription reaction. Enzymes like RNA polymerase generate large quantities of the desired RNA molecule.
  • Purification and Quality Control: The synthesized RNA is rigorously purified to remove impurities and ensure its quality and consistency. This involves techniques like filtration and chromatography.
4. Formulation and Filling:
  • Buffering and  stabilization: The purified RNA is formulated with buffers and  stabilizing agents to maintain its integrity and functionality during storage and transportation.
  • Sterile filtration and filling: The formulated RNA solution is sterile-filtered to remove any contaminants and then filled into vials or syringes under aseptic conditions.
5. Quality Control and Release:
  • Extensive testing: The final RNA product undergoes rigorous quality control testing to ensure its purity, potency, and absence of contaminants. This testing may involve gel      electrophoresis, high-performance liquid chromatography (HPLC), and other  analytical methods.
  • Release for clinical use or storage: Once all quality control parameters are met, the RNA therapeutic is released for clinical use or stored under controlledbconditions for future use.
Challenges and Considerations:
  • Scalability and Cost-Effectiveness: Scaling up production for large-scale clinical trials and commercialization can be challenging. Scientists are working on optimizing production processes to make RNA therapeutics more cost-effective.
  • Delivery System Optimization: Delivery systems are crucial for the success of RNA therapeutics. Ongoing research focuses on developing more efficient  and targeted delivery systems for improved efficacy and reduced side effects.
  • Regulatory Considerations: Regulatory agencies are still developing guidelines for RNA therapeutics. Manufacturers must comply with these  regulations to ensure the safety and efficacy of their products.
The production of RNA therapeutics is a complex process requiring expertise in various areas. However, with continued advancements, this field holds immense promise for revolutionizing healthcare and offering new treatment options for various diseases.
Additional Considerations:
  • Ethical considerations of RNA-based cancer therapies: Discuss potential risks and ethical concerns associated with RNA-based therapies, such as off-target effects  and unintended consequences.
  • Regulatory pathways for RNA-based therapeutics: This could explore the regulatory processes involved in bringing RNA-based therapies to market and ensuring patient      safety.
  • The future of RNA-based cancer therapies: Concluding discussions on the future directions of this rapidly evolving field and potential breakthroughs on the horizon.
By incorporating a mix of basic science, translational research, and clinical applications, your event can provide a comprehensive overview of the RNA revolution in oncology and its potential to transform cancer treatment.
Back to content